Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
European Radiology
Published in: European Radiology 8/2014

01-08-2014 | Oncology

Thermal ablation techniques: a curative treatment of bone metastases in selected patients?

Authors: F. Deschamps, G. Farouil, N. Ternes, A. Gaudin, A. Hakime, L. Tselikas, C. Teriitehau, E. Baudin, A. Auperin, T. de Baere

Published in: European Radiology | Issue 8/2014

Login to get access

Abstract

Introduction

Thermal ablation techniques (radiofrequency-ablation/cryotherapy) can be indicated with a curative intent. The success rate and prognostic factors for complete treatment were analysed.

Material/methods

The medical records of all patients who had undergone curatively intended thermal ablation of bone metastases between September 2001 and February 2012 were retrospectively analysed. The goal was to achieve complete treatment of all bone metastases in patients with oligometastatic disease (group 1) or only of bone metastases that could potentially lead to skeletal-related events in patients with a long life expectancy (group 2). We report the rate of complete treatment according to patient characteristics, primary tumour site, bone metastasis characteristics, radiofrequency ablation/cryotherapy and the treatment group (group 1/group 2).

Results

Eighty-nine consecutive patients had undergone curatively intended thermal ablation of 122 bone metastases. The median follow-up was 22.8 months [IQR = 12.2-44.4]. In the intent-to-treat analysis, the 1-year complete treatment rate was 67 % (95%CI: 50 %-76 %). In the multivariate analysis the favourable prognostic factors for complete local treatment were oligometastatic status (p = 0.02), metachronous (p = 0.004) and small-sized (p = 0.001) bone metastases, without cortical bone erosion (p = 0.01) or neurological structures in the vicinity (p = 0.002).

Conclusion

Thermal ablation should be included in the therapeutic arsenal for the cure of bone metastases.

Key Points

• Thermal ablation techniques are currently performed to palliate pain caused by bone metastases.
• In selected patients, thermal ablation can also be indicated with a curative intent.
• Oligometastatic and/or metachronous diseases are good prognostic factors for local success.
• Small-size (<2 cm) bone metastases and no cortical erosion are good prognostic factors.
Literature
1.
Greenlee RT, Hill-Harmon MB, Murray T, Thun M (2001) Cancer statistics, 2001. CA Cancer J Clin 51:15–36PubMedCrossRef
2.
Coleman RE (2006) Clinical features of metastatic bone disease and risk of skeletal morbidity. Clin Cancer Res 12:6243s–6249sPubMedCrossRef
3.
Hellman S, Weichselbaum RR (1995) Oligometastases. J Clin Oncol 13:8–10PubMed
4.
Weichselbaum RR, Hellman S (2011) Oligometastases revisited. Nat Rev Clin Oncol 8:378–382PubMed
5.
6.
Mayo SC, Pawlik TM (2010) Thermal ablative therapies for secondary hepatic malignancies. Cancer J 16:111–117PubMedCrossRef
7.
Thumar AB, Trabulsi EJ, Lallas CD, Brown DB (2010) Thermal ablation of renal cell carcinoma: triage, treatment, and follow-up. J Vasc Interv Radiol 21:S233–S241PubMedCrossRef
8.
9.
de Baere T (2011) Lung tumour radiofrequency ablation: where do we stand? Cardiovasc Intervent Radiol 34:241–251PubMedCrossRef
10.
11.
Gangi A, Alizadeh H, Wong L, Buy X, Dietemann JL, Roy C (2007) Osteoid osteoma: percutaneous laser ablation and follow-up in 114 patients. Radiology 242:293–301PubMedCrossRef
12.
Motamedi D, Learch TJ, Ishimitsu DN, Motamedi K, Katz MD, Brien EW, Menendez L (2009) Thermal ablation of osteoid osteoma: overview and step-by-step guide. Radiographics 29:2127–2141PubMedCrossRef
13.
Goetz MP, Callstrom MR, Charboneau JW, Farrell MA, Maus TP, Welch TJ, Wong GY, Sloan JA, Novotny PJ, Petersen IA, Beres RA, Regge D, Capanna R, Saker MB, Grönemeyer DH, Gevargez A, Ahrar K, Choti MA, de Baere TJ, Rubin J (2004) Percutaneous image-guided radiofrequency ablation of painful metastases involving bone: a multicenter study. J Clin Oncol 22:300–306PubMedCrossRef
14.
Rosenthal D, Callstrom MR (2012) Critical review and state of the art in interventional oncology: benign and metastatic disease involving bone. Radiology 262:765–780PubMedCrossRef
15.
Munk PL, Murphy KJ, Gangi A, Liu DM (2011) Fire and ice: percutaneous ablative therapies and cement injection in management of metastatic disease of the spine. Semin Musculoskelet Radiol 15:125–134PubMedCrossRef
16.
Kurup AN, Callstrom MR (2010) Ablation of skeletal metastases: current status. J Vasc Interv Radiol 21:S242–S250PubMedCrossRef
17.
Rothman KJ (1978) Estimation of confidence limits for the cumulative probability of survival in life table analysis. J Chronic Dis 31:557–560PubMedCrossRef
18.
Lo SS, Moffatt-Bruce SD, Dawson LA, Schwarz RE, Teh BS, Mayr NA, Lu JJ, Grecula JC, Olencki TE, Timmerman R (2011) The role of local therapy in the management of lung and liver oligometastases. Nat Rev Clin Oncol 8:405–416PubMedCrossRef
19.
Salama JK, Hasselle MD, Chmura SJ, Malik R, Mehta N, Yenice KM, Villaflor VM, Stadler WM, Hoffman PC, Cohen EE, Connell PP, Haraf DJ, Vokes EE, Hellman S, Weichselbaum RR (2012) Stereotactic body radiotherapy for multisite extracranial oligometastases: final report of a dose escalation trial in patients with 1 to 5 sites of metastatic disease. Cancer 118:2962–2970PubMedCrossRef
20.
Fumagalli I, Bibault JE, Dewas S, Kramar A, Mirabel X, Prevost B, Lacornerie T, Jerraya H, Lartigau E (2012) A single-institution study of stereotactic body radiotherapy for patients with unresectable visceral pulmonary or hepatic oligometastases. Radiat Oncol 7:164PubMedCentralPubMedCrossRef
21.
De Ruysscher D, Wanders R, van Baardwijk A, Dingemans AM, Reymen B, Houben R, Bootsma G, Pitz C, van Eijsden L, Geraedts W, Baumert BG, Lambin P (2012) Radical treatment of non-small-cell lung cancer patients with synchronous oligometastases: long-term results of a prospective phase II trial (Nct01282450). J Thorac Oncol 7:1547–1555PubMedCrossRef
22.
Onaitis MW, Petersen RP, Haney JC, Saltz L, Park B, Flores R, Rizk N, Bains MS, Dycoco J, D'Amico TA, Harpole DH, Kemeny N, Rusch VW, Downey R (2009) Prognostic factors for recurrence after pulmonary resection of colorectal cancer metastases. Ann Thorac Surg 87:1684–1688PubMedCrossRef
23.
Hornbech K, Ravn J, Steinbruchel DA (2011) Outcome after pulmonary metastasectomy: analysis of 5 years consecutive surgical resections 2002-2006. J Thorac Oncol 6:1733–1740PubMedCrossRef
24.
Choti MA, Sitzmann JV, Tiburi MF, Sumetchotimetha W, Rangsin R, Schulick RD, Lillemoe KD, Yeo CJ, Cameron JL (2002) Trends in long-term survival following liver resection for hepatic colorectal metastases. Ann Surg 235:759–766PubMedCentralPubMedCrossRef
25.
Orita Y, Sugitani I, Matsuura M, Ushijima M, Tsukahara K, Fujimoto Y, Kawabata K (2010) Prognostic factors and the therapeutic strategy for patients with bone metastasis from differentiated thyroid carcinoma. Surgery 147:424–431PubMedCrossRef
26.
Milano MT, Katz AW, Zhang H, Okunieff P (2012) Oligometastases treated with stereotactic body radiotherapy: long-term follow-up of prospective study. Int J Radiat Oncol Biol Phys 83:878–886PubMedCrossRef
27.
Ahmed KA, Barney BM, Davis BJ, Park SS, Kwon ED, Olivier KR (2012) Stereotactic body radiation therapy in the treatment of oligometastatic prostate cancer. Front Oncol 2:215PubMedCentralPubMedCrossRef
28.
Bernier MO, Leenhardt L, Hoang C, Aurengo A, Mary JY, Menegaux F, Enkaoua E, Turpin G, Chiras J, Saillant G, Hejblum G (2001) Survival and therapeutic modalities in patients with bone metastases of differentiated thyroid carcinomas. J Clin Endocrinol Metab 86:1568–1573PubMedCrossRef
29.
Woodward E, Jagdev S, McParland L, Clark K, Gregory W, Newsham A, Rogerson S, Hayward K, Selby P, Brown J (2011) Skeletal complications and survival in renal cancer patients with bone metastases. Bone 48:160–166PubMedCrossRef
30.
Ayala-Ramirez M, Palmer JL, Hofmann MC, de la Cruz M, Moon BS, Waguespack SG, Habra MA, Jimenez C (2013) Bone metastases and skeletal-related events in patients with malignant pheochromocytoma and sympathetic paraganglioma. J Clin Endocrinol Metab 98:1492–1497PubMedCrossRef
31.
McMenomy BP, Kurup AN, Johnson GB, Carter RE, McWilliams RR, Markovic SN, Atwell TD, Schmit GD, Morris JM, Woodrum DA, Weisbrod AJ, Rose PS, Callstrom MR (2013) Percutaneous cryoablation of musculoskeletal oligometastatic disease for complete remission. J Vasc Interv Radiol 24:207–213PubMedCrossRef
Metadata
Title
Thermal ablation techniques: a curative treatment of bone metastases in selected patients?
Authors
F. Deschamps
G. Farouil
N. Ternes
A. Gaudin
A. Hakime
L. Tselikas
C. Teriitehau
E. Baudin
A. Auperin
T. de Baere
Publication date
01-08-2014
Publisher
Springer Berlin Heidelberg
Published in
European Radiology / Issue 8/2014
Print ISSN: 0938-7994
Electronic ISSN: 1432-1084
DOI
https://doi.org/10.1007/s00330-014-3202-1

Other articles of this Issue 8/2014

European Radiology 8/2014 Go to the issue

Head and Neck

Feasibility of high-resolution pituitary MRI at 7.0 tesla

Cardiac

Reproducibility of aortic annulus measurements by computed tomography

Erratum

Erratum to: Preoperative lymph node staging in patients with primary prostate cancer: comparison and correlation of quantitative imaging parameters in diffusion-weighted imaging and 11C-choline PET/CT

Musculoskeletal

MR imaging of myxofibrosarcoma and undifferentiated sarcoma with emphasis on tail sign; diagnostic and prognostic value

Pediatric

Imaging findings in a distinct lethal inherited arteriopathy syndrome associated with a novel mutation in the FBLN4 gene

Gastrointestinal

Value of gadofosveset-enhanced MRI and multiplanar reformatting for selecting good responders after chemoradiation for rectal cancer